Sign In
Buy VRAX
$0.155
-0.0081 (-4.97%)
At Close: Jun 23, 2026
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
07:35am, Tuesday, 29'th Jul 2025
LONDON , July 29, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diag
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
04:15pm, Friday, 18'th Jul 2025
LONDON , July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagn
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating
02:57pm, Monday, 31'st Mar 2025
H.C. Wainwright initiated coverage on Virax Biolabs Group Limited VRAX, a U.K.-based company focused on detecting immune responses and diagnosing viral diseases.
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
07:30am, Tuesday, 18'th Mar 2025
LONDON , March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diag
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
07:30am, Thursday, 13'th Mar 2025
LONDON , March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diag
Virax Biolabs to Present at 19th World Immune Regulation Meeting
07:30am, Wednesday, 05'th Mar 2025
LONDON , March 5, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagn
Company Positioned to Support Public Health through Vaccine Efficacy Testing and Data-Driven Insights into Patients' Immune Profiles to Empower Informed Decisions on Vaccination LONDON , Feb. 25, 2025
CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovati
CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
07:30am, Tuesday, 17'th Dec 2024
LONDON , Dec. 17, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses to and di
LONDON , Dec. 10, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagn
Virax Biolabs Announces Distribution Agreement with Europa Biosite to Commercialize ImmuneSelect in the United Kingdom and Ireland
07:30am, Wednesday, 23'rd Oct 2024
LONDON , Oct. 23, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagn
CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group engaged in innovativ
LONDON , Sept. 16, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diag
Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference
08:00am, Monday, 09'th Sep 2024
LONDON , Sept. 9, 2024 /PRNewswire/ -- Virax Biolabs ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral
